Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 611 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Interstitial Disease Clear all
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 10, 2026, 1:21 AM EDT
Not listed Early Phase 1 Interventional

Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil

NCT06011785
View directory record Official record
Conditions
Silicosis
Interventions
Silica 12CH
Drug
Lead sponsor
HOHM Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

NCT00352482
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil (50 mg)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 10, 2026, 1:21 AM EDT
Terminated No phase listed Observational

Stromal Gene Expression During Pulmonary Sarcoidosis

NCT00837668
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCT03220035
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions
Laboratory Biomarker Analysis, Vemurafenib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 10, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

NCT01280994
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Hyperpolarized 129Xenon Gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

NCT03573505
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 10, 2026, 1:21 AM EDT
Not yet recruiting Phase 3 Interventional

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
2,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

NCT04552899
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151 (Zinpentraxin Alfa), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT00678821
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Aerobic exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 82 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

NCT02788474
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Targeting Oxidative Stress in Chronic Beryllium Disease

NCT01088243
View directory record Official record
Conditions
Chronic Beryllium Disease
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 10, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774
View directory record Official record
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321420
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo, Pirfenidone, Deupirfenidone
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 10, 2026, 1:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

NCT03500731
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

NCT03727802
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
TRK-250, Placebo
Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 10, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease

NCT06751069
View directory record Official record
Conditions
Lung Fibrosis, Lung Interstitial Disease
Interventions
Home-based Pulmonary Rehab
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 10, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

NCT04396756
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 10, 2026, 1:21 AM EDT
Completed No phase listed Observational

Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis

NCT01107028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard pulmonary rehabilitation program
Other
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 10, 2026, 1:21 AM EDT